Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385399650> ?p ?o ?g. }
- W4385399650 endingPage "2046" @default.
- W4385399650 startingPage "2046" @default.
- W4385399650 abstract "Cutaneous leishmaniasis (CL) is a public health problem affecting more than 98 countries worldwide. No vaccine is available to prevent the disease, and available medical treatments cause serious side effects. Additionally, treatment failure and parasite resistance have made the development of new drugs against CL necessary. In this work, a virtual screening of natural products from the BIOFACQUIM and Selleckchem databases was performed using the method of molecular docking at the triosephosphate isomerase (TIM) enzyme interface of Leishmania mexicana (L. mexicana). Finally, the in vitro leishmanicidal activity of selected compounds against two strains of L. mexicana, their cytotoxicity, and selectivity index were determined. The top ten compounds were obtained based on the docking results. Four were selected for further in silico analysis. The ADME-Tox analysis of the selected compounds predicted favorable physicochemical and toxicological properties. Among these four compounds, S-8 (IC50 = 55 µM) demonstrated a two-fold higher activity against the promastigote of both L. mexicana strains than the reference drug glucantime (IC50 = 133 µM). This finding encourages the screening of natural products as new anti-leishmania agents." @default.
- W4385399650 created "2023-07-31" @default.
- W4385399650 creator A5010595959 @default.
- W4385399650 creator A5011959763 @default.
- W4385399650 creator A5042470942 @default.
- W4385399650 creator A5047766184 @default.
- W4385399650 creator A5052759042 @default.
- W4385399650 creator A5054495552 @default.
- W4385399650 creator A5055524253 @default.
- W4385399650 creator A5066760747 @default.
- W4385399650 creator A5088702135 @default.
- W4385399650 creator A5089745349 @default.
- W4385399650 creator A5091518399 @default.
- W4385399650 date "2023-07-29" @default.
- W4385399650 modified "2023-10-17" @default.
- W4385399650 title "Triose Phosphate Isomerase Structure-Based Virtual Screening and In Vitro Biological Activity of Natural Products as Leishmania mexicana Inhibitors" @default.
- W4385399650 cites W1031578623 @default.
- W4385399650 cites W1198437613 @default.
- W4385399650 cites W1966404472 @default.
- W4385399650 cites W1971772901 @default.
- W4385399650 cites W1980363117 @default.
- W4385399650 cites W1995766329 @default.
- W4385399650 cites W2001021359 @default.
- W4385399650 cites W2053396751 @default.
- W4385399650 cites W2071334030 @default.
- W4385399650 cites W2083952632 @default.
- W4385399650 cites W2087262141 @default.
- W4385399650 cites W2100063740 @default.
- W4385399650 cites W2105105987 @default.
- W4385399650 cites W2132629607 @default.
- W4385399650 cites W2134967712 @default.
- W4385399650 cites W2169678694 @default.
- W4385399650 cites W2173491550 @default.
- W4385399650 cites W2379628571 @default.
- W4385399650 cites W2560436137 @default.
- W4385399650 cites W2593436234 @default.
- W4385399650 cites W2801088198 @default.
- W4385399650 cites W2887773924 @default.
- W4385399650 cites W2902341473 @default.
- W4385399650 cites W2930586545 @default.
- W4385399650 cites W2937934916 @default.
- W4385399650 cites W2942187023 @default.
- W4385399650 cites W2945386680 @default.
- W4385399650 cites W2972203631 @default.
- W4385399650 cites W2980919108 @default.
- W4385399650 cites W2986091153 @default.
- W4385399650 cites W2989653758 @default.
- W4385399650 cites W2999028971 @default.
- W4385399650 cites W3010301298 @default.
- W4385399650 cites W3020261787 @default.
- W4385399650 cites W3035720303 @default.
- W4385399650 cites W3098888840 @default.
- W4385399650 cites W3145192567 @default.
- W4385399650 cites W3159177617 @default.
- W4385399650 cites W3164382875 @default.
- W4385399650 cites W3164677698 @default.
- W4385399650 cites W3174916508 @default.
- W4385399650 cites W3177960752 @default.
- W4385399650 cites W3196327336 @default.
- W4385399650 cites W3199507181 @default.
- W4385399650 cites W3200415922 @default.
- W4385399650 cites W3207533279 @default.
- W4385399650 cites W4206323110 @default.
- W4385399650 cites W4211073781 @default.
- W4385399650 cites W4211081013 @default.
- W4385399650 cites W4225932677 @default.
- W4385399650 cites W4231743556 @default.
- W4385399650 cites W4251446263 @default.
- W4385399650 cites W4292231042 @default.
- W4385399650 cites W4294740761 @default.
- W4385399650 cites W4297489880 @default.
- W4385399650 cites W4321106231 @default.
- W4385399650 cites W4323314092 @default.
- W4385399650 cites W4362048439 @default.
- W4385399650 cites W2969289544 @default.
- W4385399650 doi "https://doi.org/10.3390/pharmaceutics15082046" @default.
- W4385399650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37631260" @default.
- W4385399650 hasPublicationYear "2023" @default.
- W4385399650 type Work @default.
- W4385399650 citedByCount "0" @default.
- W4385399650 crossrefType "journal-article" @default.
- W4385399650 hasAuthorship W4385399650A5010595959 @default.
- W4385399650 hasAuthorship W4385399650A5011959763 @default.
- W4385399650 hasAuthorship W4385399650A5042470942 @default.
- W4385399650 hasAuthorship W4385399650A5047766184 @default.
- W4385399650 hasAuthorship W4385399650A5052759042 @default.
- W4385399650 hasAuthorship W4385399650A5054495552 @default.
- W4385399650 hasAuthorship W4385399650A5055524253 @default.
- W4385399650 hasAuthorship W4385399650A5066760747 @default.
- W4385399650 hasAuthorship W4385399650A5088702135 @default.
- W4385399650 hasAuthorship W4385399650A5089745349 @default.
- W4385399650 hasAuthorship W4385399650A5091518399 @default.
- W4385399650 hasBestOaLocation W43853996501 @default.
- W4385399650 hasConcept C103697762 @default.
- W4385399650 hasConcept C104317684 @default.
- W4385399650 hasConcept C109316439 @default.
- W4385399650 hasConcept C136764020 @default.
- W4385399650 hasConcept C159110408 @default.